Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure www.poweroverpressure.com.

Slides:



Advertisements
Similar presentations
© 2008, American Heart Association. All rights reserved. AHA 2008 Resistant Hypertension: Diagnosis, Evaluation, and Treatment Slide Set David A. Calhoun,
Advertisements

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
Treatment-Resistant Hypertension: Management Approaches Power Over Pressure
JNC 8 Guidelines….
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Treatment-Resistant Hypertension: Diagnosis and Management Power Over Pressure
Treatment-Resistant Hypertension: Diagnosis and Management Power Over Pressure
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
Bridget Dillon February 11,  Cardiovascular disease affects the heart and circulatory system. It is often a result of blockages of blood vessels.
Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
The need for a triple-drug fixed-dose combination in hypertension
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
The concept of Diabetes & CV risk: A lifetime risk challenge
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Pharmacological Treatment of Hypertension Update 2012.
OPTIMAL BLOOD PRESSURE LEVELS IN ELDERLY PERSONS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) COHORT STUDY Maciej Banach*,
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
Clinical Characteristic of Patients with Uncontrolled, Potentially Under-treated and Apparent Treatment Resistant Hypertension: NHANES 1988  Brent.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
1 Current & New treatment strategies to address CV Risk.
54a. Percentage of workers who smoke, selected occupations, 2010 (All employment)
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.
HvC Comparative Effectiveness Project Groups 5 and 6
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015.
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
2007 Hypertension as a Public Health Risk January, 2007.
Quality and Costs: A Twisted Relationship L. Gregory Pawlson MD, MPH, FACP Executive Vice President NCQA.
Blood pressure control: Where do we stand? Latest data from Italy Tocci G et al. J Hypertens. 2012;30:
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Cardiovascular Risk: A global perspective
Antonio Coca, MD, PhD, FRCP, FESC
Hypertension guidelines What’s all the controversy about 2015
Judith H. Veis, MD, FACP Associate Director, Nephrology
Renal Denervation Next Steps
What’s New in the 2013 ESC/ESH Hypertension Guideline
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Progress and Promise in RAAS Blockade
Managing Complex Hypertension: What Every Physician Should Know
برنامه راهبردی پیشگیری و کنترل بیماری های قلبی عروقی
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Management of hypertension in patients with chronic kidney disease
Global burden of hypertension in the adult population
Managing Age-Related Clinical Issues in Hemophilia
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Guidelines for the Older Adult With CKD
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
JNC Evidence-Based Guideline for the Management of
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
JNC Evidence-Based Guideline for the Management of
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure

“Hypertension: uncontrolled and conquering the world” Volume 370, Issue 9587, August 18, 2007, Page 539 Number of People With Hypertension (millions) * Year 972 million (26%) 1.56 billion (29%) Lack of BP Control in Treated Hypertensive Patients † (%) 47% 59% 66% 71% 39% 50% 84% *Projected. Most of the expected increase will be in economically developing regions. † Based on a literature search of the MEDLINE database of studies from January 1980 through July Kearney PM, et al. Lancet. 2005;365: Kearney PM, et al. J Hypertens. 2004; 22: Hypertension: a substantial and growing problem 1 Lack of BP control is widespread, despite treatment 2 Power Over Pressure

A particularly complex clinical challenge BP that remains above goal, in spite of… *All medications should be titrated to the maximum in-label doses or until BP control is achieved, except in cases of intolerance, in which case treatments should be optimized to the maximum tolerated doses † Patients who require  4 antihypertensive agents to achieve BP control are also considered treatment resistant, according to some sources. 1 1.Calhoun DA, et al. Circulation. 2008;117:e510-e Mancia G, et al. Eur Heart J. 2007;28: Treatment-resistant hypertension is defined as: 1,2 compliance with maximum doses*… of  3 antihypertensive medications † … from different classes, ideally including a diuretic… BP Goal Reversible causes identified and addressed Power Over Pressure

A common and increasing problem 1.Persell, S. Hypertension. 2011;57: Hypertension and cardiovascular disease. World Heart Federation federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/hypertension/. Accessed March 2, Lloyd-Jones D, et al. Circulation. 2010;121:e46-e Calhoun DA, et al. Circulation. 2008;117:e510-e Egan BM, et al. Circulation. 2011;124: million people worldwide (15% to 20% of uncontrolled hypertension) are estimated to have treatment-resistant hypertension 1,2,3 Despite focused efforts, the percentage of patients resistant to treatment has not fallen with newer medications and strategies; rather it has increased by 62% in the last 20 years* 4,5 *In the time periods vs , the proportion of treated uncontrolled hypertensive patients reportedly taking ≥3 BP medications increased from 16% to 28%. Power Over Pressure

Treatment-resistant hypertension is associated with a substantially increased risk of CV events CV=cardiovascular. Adapted from Pierdomenico SD, et al. Am J Hypertens. 2005;18: Differences between groups were apparent from very early in the follow-up period, indicating the urgent need for BP control in patients with treatment- resistant hypertension. CV Event Rate (5-year follow-up) Controlled Hypertension 5% Treatment Resistant19% Power Over Pressure Note: Study did not include outcomes in untreated hypertensives or in patients with uncontrolled hypertension on 1-2 antihypertensive medications.

Summary: treatment-resistant hypertension Hypertension is –common and likely to increase –estimated to affect 1.56 billion people worldwide by 2025 –elusive and difficult to control even in treated patients –a risk factor for CV disease when uncontrolled Treatment-resistant hypertension is defined as BP that remains above goal despite compliance with ≥3 antihypertensive medications –100 million people worldwide are estimated to have treatment-resistant hypertension –Prevalence will likely increase due to increasingly older age and more obese populations –Diabetes and chronic kidney disease (CKD) are risk factors Patients with treatment-resistant hypertension are at increased risk of CV events –Based on a 5-year CV event follow-up, 19% of patients with treatment-resistant hypertension experienced an event compared with 5% of patients with controlled hypertension Power Over Pressure